BACKGROUND: Patients with diabetes mellitus (DM) undergoing coronary revascularization are at increased risk for adverse outcomes. Without sufficiently powered data from diabetic subgroup analyses and in absence of randomized controlled trials in diabetic patients with primary clinical outcomes controversy is ongoing over safety and efficacy of drug-eluting stents (DES) in diabetic patients. METHODS AND RESULTS: Between October 2005 and October 2006, 1,659 diabetic and 3,559 non-diabetic patients treated with DES (Paclitaxel or Sirolimus-eluting stents) were enrolled at 98 Drug-Eluting-Stent.DEutschland (DES.DE) sites. Major adverse cardiac and cerebrovascular events (MACCE), defined as the composite of death, myocardial infarction, and stroke, as well as target vessel revascularization (TVR) were defined as primary endpoints. The baseline clinical and descriptive morphology of coronary artery disease revealed more severe findings in diabetic patients. At 1-year follow-up, diabetic patients treated with DES had significantly higher rates for overall death (5.6 vs. 3.4%; p < 0.01), myocardial infarction (4.8 vs. 3.4%; p = 0.05), stroke (1.7 vs. 0.9%; p < 0.05), MACCE (10.9 vs. 7.1%; p < 0.001), and overall stent thrombosis (4.9 vs. 3.3%; p < 0.01) with slightly elevated rates for TVR (12.0 vs. 10.4%; p = 0.17); data which remained after risk-adjustment. CONCLUSION: Data collected in DES.DE revealed that despite the use of DES the risk of myocardial infarction, death, and thrombotic events remains higher in diabetic patients.
BACKGROUND:Patients with diabetes mellitus (DM) undergoing coronary revascularization are at increased risk for adverse outcomes. Without sufficiently powered data from diabetic subgroup analyses and in absence of randomized controlled trials in diabeticpatients with primary clinical outcomes controversy is ongoing over safety and efficacy of drug-eluting stents (DES) in diabeticpatients. METHODS AND RESULTS: Between October 2005 and October 2006, 1,659 diabetic and 3,559 non-diabeticpatients treated with DES (Paclitaxel or Sirolimus-eluting stents) were enrolled at 98 Drug-Eluting-Stent.DEutschland (DES.DE) sites. Major adverse cardiac and cerebrovascular events (MACCE), defined as the composite of death, myocardial infarction, and stroke, as well as target vessel revascularization (TVR) were defined as primary endpoints. The baseline clinical and descriptive morphology of coronary artery disease revealed more severe findings in diabeticpatients. At 1-year follow-up, diabeticpatients treated with DES had significantly higher rates for overall death (5.6 vs. 3.4%; p < 0.01), myocardial infarction (4.8 vs. 3.4%; p = 0.05), stroke (1.7 vs. 0.9%; p < 0.05), MACCE (10.9 vs. 7.1%; p < 0.001), and overall stent thrombosis (4.9 vs. 3.3%; p < 0.01) with slightly elevated rates for TVR (12.0 vs. 10.4%; p = 0.17); data which remained after risk-adjustment. CONCLUSION: Data collected in DES.DE revealed that despite the use of DES the risk of myocardial infarction, death, and thrombotic events remains higher in diabeticpatients.
Authors: Lars Rydén; Eberhard Standl; Małgorzata Bartnik; Greet Van den Berghe; John Betteridge; Menko-Jan de Boer; Francesco Cosentino; Bengt Jönsson; Markku Laakso; Klas Malmberg; Silvia Priori; Jan Ostergren; Jaakko Tuomilehto; Inga Thrainsdottir; Ilse Vanhorebeek; Marco Stramba-Badiale; Peter Lindgren; Qing Qiao; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; John Camm; Veronica Dean; Jaap Deckers; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; João Morais; Ady Osterspey; Juan Tamargo; José Luis Zamorano; Jaap W Deckers; Michel Bertrand; Bernard Charbonnel; Erland Erdmann; Ele Ferrannini; Allan Flyvbjerg; Helmut Gohlke; Jose Ramon Gonzalez Juanatey; Ian Graham; Pedro Filipe Monteiro; Klaus Parhofer; Kalevi Pyörälä; Itamar Raz; Guntram Schernthaner; Massimo Volpe; David Wood Journal: Eur Heart J Date: 2007-01 Impact factor: 29.983
Authors: H Schühlen; A Kastrati; J Dirschinger; J Hausleiter; S Elezi; A Wehinger; J Pache; M Hadamitzky; A Schömig Journal: Circulation Date: 1998-07-14 Impact factor: 29.690
Authors: Andrew T L Ong; Patrick W Serruys; Jiro Aoki; Angela Hoye; Carlos A G van Mieghem; Gaston A Rodriguez-Granillo; Marco Valgimigli; Karel Sonnenschein; Evelyn Regar; Martin van der Ent; Peter P T de Jaegere; Eugene P McFadden; Georgios Sianos; Willem J van der Giessen; Pim J de Feyter; Ron T van Domburg Journal: J Am Coll Cardiol Date: 2005-04-05 Impact factor: 24.094
Authors: A Abizaid; R Kornowski; G S Mintz; M K Hong; A S Abizaid; R Mehran; A D Pichard; K M Kent; L F Satler; H Wu; J J Popma; M B Leon Journal: J Am Coll Cardiol Date: 1998-09 Impact factor: 24.094
Authors: Christoph Stettler; Simon Wandel; Sabin Allemann; Adnan Kastrati; Marie Claude Morice; Albert Schömig; Matthias E Pfisterer; Gregg W Stone; Martin B Leon; José Suarez de Lezo; Jean-Jacques Goy; Seung-Jung Park; Manel Sabaté; Maarten J Suttorp; Henning Kelbaek; Christian Spaulding; Maurizio Menichelli; Paul Vermeersch; Maurits T Dirksen; Pavel Cervinka; Anna Sonia Petronio; Alain J Nordmann; Peter Diem; Bernhard Meier; Marcel Zwahlen; Stephan Reichenbach; Sven Trelle; Stephan Windecker; Peter Jüni Journal: Lancet Date: 2007-09-15 Impact factor: 79.321
Authors: K Drechsler; S Fikenzer; U Sechtem; E Blank; G Breithardt; U Zeymer; J Niebauer Journal: Clin Res Cardiol Date: 2008-02-04 Impact factor: 5.460
Authors: Pallav Garg; Sharon-Lise T Normand; Treacy S Silbaugh; Robert E Wolf; Katya Zelevinsky; Ann Lovett; Manu R Varma; Zheng Zhou; Laura Mauri Journal: Circulation Date: 2008-11-10 Impact factor: 29.690
Authors: Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns Journal: Eur Heart J Date: 2005-03-15 Impact factor: 29.983
Authors: Ibrahim Akin; Marcus Wiemer; Steffen Schneider; Jochen Senges; Matthias Hochadel; Gert Richardt; Mohamed Abdel-Wahab; Karl-Heinz Kuck; Christoph A Nienaber Journal: Clin Res Cardiol Date: 2011-11-13 Impact factor: 5.460
Authors: Klaus Bonaventura; Alexander W Leber; Christian Sohns; Mattias Roser; Leif-Hendrik Boldt; Franz X Kleber; Wilhelm Haverkamp; Marc Dorenkamp Journal: Clin Res Cardiol Date: 2012-02-21 Impact factor: 5.460
Authors: Timm Bauer; Christoph A Nienaber; Ibrahim Akin; Karl-Heinz Kuck; Matthias Hochadel; Jochen Senges; Thomas Fetsch; Ulrich Tebbe; Stefan N Willich; Jürgen Stumpf; Georg V Sabin; Sigmund Silber; Gert Richardt; Ralf Zahn Journal: Clin Res Cardiol Date: 2011-03-18 Impact factor: 5.460
Authors: Antoinette de Waha; Alban Dibra; Sebastian Kufner; Dietrich Baumgart; Manel Sabate; Aleardo Maresta; Albert Schömig; Adnan Kastrati Journal: Clin Res Cardiol Date: 2011-01-08 Impact factor: 5.460
Authors: Matthias Leschke; Vo Thanh Nhan; Matthias Waliszewski; Vicente Palacios; Iván Horváth; Vladimir A Ivanov; Damras Tresukosol; Panicos Avraamides; André Schneider; Martin Unverdorben Journal: Indian Heart J Date: 2012-08-27